Румунија - Румунски - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lek pharmaceuticals d.d. - slovenia - darunavirum - compr. film. - 400mg - antivirale cu actiune directa inhibitori de proteaza

Румунија - Румунски - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lek pharmaceuticals d.d. - slovenia - darunavirum - compr. film. - 800mg - antivirale cu actiune directa inhibitori de proteaza

Румунија - Румунски - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

teva operations poland sp. z.o.o. - polonia - darunavirum - compr. film. - 600mg - antivirale cu actiune directa inhibitori de proteaza

Румунија - Румунски - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lek pharmaceuticals d.d. - slovenia - darunavirum - compr. film. - 600mg - antivirale cu actiune directa inhibitori de proteaza

Европска Унија - Румунски - EMA (European Medicines Agency)

janssen-cilag international n.v. - darunavir, cobicistat - infecții cu hiv - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - rezolsta, este indicat în combinatie cu alte medicamente antiretrovirale pentru tratamentul de virusul imunodeficienţei umane 1 (hiv 1) infecţie la adulţi în vârstă de 18 ani sau mai în vârstă. genotipice de testare ar trebui să ghideze utilizarea rezolsta.

Европска Унија - Румунски - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - infecții cu hiv - antivirale pentru uz sistemic - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Европска Унија - Румунски - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir, cobicistat, emtricitabină, tenofovir alafenamide - infecții cu hiv - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza este indicat pentru tratamentul de virusul imunodeficienţei umane de tip 1 de infectare (hiv‑1) la adulţi şi adolescenţi (cu vârsta de 12 ani şi mai în vârstă cu corp greutate cel puţin 40 kg). genotypic testing should guide the use of symtuza.

Румунија - Румунски - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

teva pharmaceuticals s.r.l. - darunavirum - compr. film. - 400mg - antivirale cu actiune directa inhibitori de proteaza

Румунија - Румунски - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

krka, d.d., novo mesto - slovenia - darunavirum - compr. film. - 400mg - antivirale cu actiune directa inhibitori de proteaza

Румунија - Румунски - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

krka, d.d., novo mesto - slovenia - darunavirum - compr. film. - 600mg - antivirale cu actiune directa inhibitori de proteaza